Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan

References

• Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039–52.
   PubMed Web of Science ®Google Scholar
• Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51:321–5.
   PubMed Web of Science ®Google Scholar
• Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661–7.
   PubMed Web of Science ®Google Scholar
• Rai SK, Aviña-Zubieta JA, McCormick N, De Vera MA, Shojania K, Sayre EC, et al. The rising prevalence and incidence of gout in British Columbia, Canada:Population-based trends from 2000 to 2012. Semin Arthritis Rheum. 2017;46(4):451–6.
   PubMed Web of Science ®Google Scholar
• Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010;20(5):413–9.
   PubMed Web of Science ®Google Scholar
• Ministry of Health Labour and Welfare. Annual Health, Labor and Welfare Report 2015, Health and Medical Services. Available from: http://www.mhlw.go.jp/english/wp/wp-hw9/dl/02e.pdf.
   Google Scholar
• Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol. 2014;18(6):876–84.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–41.
   PubMed Web of Science ®Google Scholar
• Winnard D, Wright C, Taylor WJ, Jackson G, Karu LT, Gow PJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology (Oxford). 2012;51(5):901–9.
   PubMed Web of Science ®Google Scholar
• Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165(7):742–8.
   PubMed Web of Science ®Google Scholar
• Aune D, Norat T, Vatten LJ. Body mass index and the risk of gout: a systematic review and dose-response meta-analysis of prospective studies. Eur J Nutr. 2014;53(8):1591–601.
   PubMed Web of Science ®Google Scholar
• Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–81.
   PubMed Web of Science ®Google Scholar
• Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis. 2013;72(5):694–700.
   PubMed Web of Science ®Google Scholar
• Wändell P, Carlsson AC, Ljunggren G. Gout and its comorbidities in the total population of Stockholm. Prev Med. 2015;81:387–91.
   PubMed Web of Science ®Google Scholar
• Dehlin M, Drivelegka P, Sigurdardottir V, Svärd A, Jacobsson LT. Incidence and prevalence of gout in Western Sweden. Arthritis Res Ther. 2016;18(1):164.
   PubMedGoogle Scholar
• Kuo CF, Grainge MJ, See LC, Yu KH, Luo SF, Zhang W, et al. Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther. 2015;17(1):13.
   PubMedGoogle Scholar
• Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82(3):421–6.
   PubMedGoogle Scholar
• Bhole V, de Vera M, Rahman MM, Krishnan E, Choi H. Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort . Arthritis Rheum. 2010;62(4):1069–76.
   PubMed Web of Science ®Google Scholar
• Hakoda M. Recent trends in hyperuricemia and gout in Japan. Japan Med Assoc J. 2012;55(4):319–23.
   PubMedGoogle Scholar
• Ministry of Health, Labor and Welfare, Japan. Outline for the results of the National Health and Nutrition Survey Japan, Tokyo, Japan. 2007. Available from: http://www.nibiohn.go.jp/eiken/english/research/pdf/nhns2007.pdf
   Google Scholar
• Kumar AUA, Browne LD, Li X, Adeeb F, Perez-Ruiz F, Fraser AD, et al. Temporal trends in hyperuricaemia in the Irish health system from 2006–2014: A cohort study. PLoS One. 2018;13(5):e0198197.
   PubMed Web of Science ®Google Scholar
• Terrill M, Riordan J. A survey of the assessment and management of gout in general practitioners and medical officers within the Illawarra Network, Australia. Int J Rheum Dis. 2017;20(8):990.
   PubMed Web of Science ®Google Scholar
• Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925–34.
   PubMed Web of Science ®Google Scholar
• Robinson PC, Taylor WJ, Dalbeth N. An observational study of gout prevalence and quality of care in a National Australian General Practice population. J Rheumatol. 2015;42(9):1702–7.
   PubMed Web of Science ®Google Scholar
• Yamanaka H. Japanese Society of Gout and Nucleic Acid Metabolism.Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018–29.
   PubMed Web of Science ®Google Scholar
• Ichikawa N, Taniguchi A, Urano W, Nakajima A, Yamanaka H. Comorbidities in patients with gout. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1045–50.
   PubMed Web of Science ®Google Scholar
• Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al. British Society for Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2017;56(7):e1–e20.
   PubMedGoogle Scholar
• Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431–46. 2012
   PubMed Web of Science ®Google Scholar
• Wakasugi M, Kazama JJ, Narita I, Konta T, Fujimoto S, Iseki K, et al. Association between hypouricemia and reduced kidney function: a cross-sectional population-based study in Japan. Am J Nephrol. 2015;41(2):138–46.
   PubMed Web of Science ®Google Scholar
• Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women–the Third National Health and Nutrition Examination Survey. Arthritis Res Ther. 2008;10(5):R116.
   PubMed Web of Science ®Google Scholar
• Tamada T, Iwasaki H. Age at natural menopause in Japanese women (in Japanese.). Acta Obst Gynaec Jpn. 1995;47:947–52.
   Google Scholar
• Ministry of Health, Labor and Welfare, Japan. Comprehensive Survey of Living Conditions. Rate of Outpatients (Per 1000 Population) by Type of Diseases, Gender and Age Group (Multiple Answer), 2013.
   Google Scholar
• Kawasaki T, shichikawa K. Prevalence of gout in population-based epidemiological study in Japan. Ann Rheum Dis. 2007;66(2):S232.
   Google Scholar